Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 

Title:  Composition for alleviating symptoms of uremia in patients

United States Patent:  6,706,263

Issued:  March 16, 2004

Inventors:  Ranganathan; Natarajan (Broomall, PA); Dickstein; Jack (Huntingdon Valley, PA)

Assignee:  Kibow Biotech Inc. (Philadelphia, PA)

Appl. No.:  557011

Filed:  April 20, 2000

Abstract

Microencapsulated and/or enteric coated compositions containing a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules and a bacterial source which metabolizes urea and ammonia are provided. Also provided are methods of using these compositions to alleviate symptoms of uremia in patients.

SUMMARY OF THE INVENTION

An object of the present invention is to provide microencapsulated and/or enteric coated compositions which comprise a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules; and a bacterial source which metabolizes urea and ammonia for use in patients in the alleviation of symptoms associated with uremia.

Another object of the present invention is to provide a method of alleviating symptoms of uremia in a patient which comprises administering orally to a patient suffering from uremia a microencapsulated and/or enteric coated composition comprising a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecules; and a bacterial source which metabolizes urea and ammonia.

DETAILED DESCRIPTION OF THE INVENTION

In kidney failure there is a decrease in the glomerular filtration rate and the kidneys are unable to maintain homeostasis of the blood. Homeostatic balance of water, sodium, potassium, calcium and other salts is no longer possible and nitrogenous wastes are not excreted. Retention of water causes edema and as the concentration of hydrogen ions increases, acidosis develops. Nitrogenous wastes accumulate and a condition referred to as uremia develops in the blood and tissue. Uremic toxins can be defined as solutes that: (I) are normally excreted by healthy kidneys, (ii) accumulate progressively during the development of renal failure so that their concentration increases, and (iii) inhibit various physiologic and biochemical functions; as a whole, they contribute to a complex set of clinical symptoms that comprise the Uremic Syndrome. Examples of uremic toxins include, but are not limited to, ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules. More specifically, in uremia, the concentration of serum creatinine, blood urea nitrogen (BUN), uric acid, and guanidino compounds such as N-methyl guanidine (NMG) and guanidino succinic acid (GSA) are significantly altered with accompanying abnormalities in acid-base equilibrium, electrolytes and water retention. In addition, there are several known and unknown substances of low and middle molecular weight which have been identified as uremic toxins which also accumulate. If untreated the acidosis and uremia can cause coma and eventually death.

Further, as a result of poor clearance of waste products of metabolism, there are some compensatory as well as adaptive processes, which further complicate the condition. For example, bacterial overgrowth of the normal flora of the gut occurs when kidney function is reduced to less than 20% and creatinine levels in the serum increase to 8 mg/dl. Substantially increased metabolism of normal substrates and a large variety of toxic amines, such as methylamine, dimethylamine, trimethylamine, phenols and indole metabolites also occurs from this bacterial outgrowth. When the small gut bacterial growth increases, there is an increase in ammonia release which then enters the enterohepatic circulation and is converted to urea.

The introduction of renal dialysis has contributed to rapid progress in the clinical treatment of renal failure and elucidation of uremia. When a patient has mild kidney failure where the serum creatinine level is less than 400 .mu.mol/L, the patient does not require renal replacement therapy such as dialysis or renal transplant. However, in general, when the serum creatinine level rises to 900 .mu.mol/L, the patient needs routine dialysis or a kidney transplant to survive.

Dialysis can serve as a lifetime therapy for ESRD patients. Phosphate binders such as calcium acetate, calcium carbonate or aluminum hydroxide are generally prescribed for uremic patients receiving dialysis to reduce elevated phosphate levels. In general, however, dialysis is very expensive, inconvenient, time consuming and may occasionally produce one or more side effects. With a successful kidney transplant, a patient can live a more normal life with less long-term expense. However, there are also high costs associated with transplant surgery, the recovery period and the continuous need for antirejection medications. Further, there is oftentimes a shortage of suitable donors. Accordingly there is a need for alternative strategies.

In the present invention, compositions are provided which comprise a mixture of sorbents selected for their specific adsorption affinities for uremic toxins such as ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules. For example, in a preferred embodiment, the mixture of sorbents comprises: oxystarch or oxycellulose with a specific adsorption affinity for urea and ammonia; locust bean gum with a specific adsorption affinity for creatinine and urea; and activated charcoal with a specific adsorption affinity for creatinine guanidines, phenol, Indican and middle molecular weight undefined components. Compositions of the present invention further comprise a bacterial source which metabolizes urea and ammonia, preferably to amino acids which can be used by the bacteria or the patient. Examples of bacterial sources useful in the present invention include, but are not limited, E. coli DH5, Sprosarcina urae and genetically modified yeast cells such as S. pombe. The composition is then enteric coated and/or microencapsulated. Enteric coating of the composition is specifically designed to deliver the sorbents and bacterial source at the ileal and colonic regions of the bowel where maximal resorption of uremic solutes and other molecules are found to occur. This is preferably achieved via an enteric coating material which disintegrates and dissolves at a pH of 7.5 or higher. Examples of enteric coatings with these characteristics include, but are not limited to, Zein, polyglycolactic acid, polylactic acid, polylactide-coglycolide and similar coating materials. Enteric coatings also enable delivery of the sorbents to their site of action in relatively native form without binding of various digestive materials to the sorbents prior to reaching the target region. Alternatively, or in addition, the compositions of the present invention can be microencapsulated thus permitting the compositions to perform like microscopic dialysis units as described by Chang, T. M. S. (Artificial Cells, Chapter 5, in Biomedical Applications of Microencapsulation, edited by Lim, F. CRC Press Fla., pp 86-100). In this embodiment, the composition is coated with a non-absorbable polymeric compound which permits only small and middle-sized molecules into the core wherein the mixture of solvent and bacterial source are located. Examples of non-absorbable polymeric coatings for microencapsulation include, but are not limited to, alginate/alginic acid, chitosan, cellulose acetate pthalate, hydroxyethyl cellulose and similar coating materials. Microencapsulation prevents the binding of macromolecules and other digestive materials which substantially reduce the efficacy of the sorbents to specifically adsorb the uremic solutes to the sorbents of the mixture. The microcapsules pass through the bowel, with the mixture of sorbents adsorbing multiple uremic solutes and the bacterial source metabolizing urea and ammonia and urea, and are then excreted intact from the bowel. Thus, in this embodiment, the patient is protected from the possibility of microbial infection by the bacterial source as the bacterial source is kept within the microcapsule. Accordingly, in a preferred embodiment, compositions of the present invention are both microencapsulated and enteric coated.

Compositions of the present invention may further comprise a phosphate binding agent such as aluminium hydroxide, calcium carbonate or calcium acetate and a water binding agent such as psyllium fibers, naturally occurring gums or modified starches.

Compositions of the present invention are administered orally to patients with uremia to alleviate the symptoms of uremia. By "alleviation of symptoms" of uremia, it is meant that the composition removes sufficient levels of uremic toxins such that a patient suffering from uremia either does not require dialysis, requires dialysis less frequently or for shorter durations, or does not require initiation of dialysis as soon.

In a preferred embodiment, oral delivery of the mixture of sorbents in the composition will be accomplished via a 2 to 4 ounce emulsion or paste mixed with an easy to eat food such as a milk shake or yogurt. The microencapsulated bacterial source can be administered along with the mixture of sorbents in the emulsion or paste or separately in a swallowable gelatin capsule.

A mathematical model of solute transport of oral sorbents has been developed based on the diffusion controlled solute flux into the intestinal lumen followed by physical binding or chemical trapping (Gotch et al. Journal of Dialysis 1976-1977 1(2):105-144). This model provides the theoretical basis of solute removal through the gut.

For example, gut clearance of urea is 10 to 12 ml/minute in normal renal function and is reduced to 3 to 4 ml/minute in patients with severely reduced renal function. This reduction in the clearance rate is independent of blood urea concentration and directly related to impaired renal function. The normal creatinine clearance rate is 2 to 5 ml/minute.

Further, at steady state, as rate of mass generation is equal to rate of mass elimination, the first order sorbent promoted gut clearance of any solute is given by the mass balance equation:

Gs =(Kr +Kg)Cs,

where Gs =rate of solute generated, Kr =rate of renal clearance, Kg =rate of gut clearance and Cs is concentration of solute.

The process of sorbent binding, for a given amount of sorbent, is saturable. Thus, below the saturation levels, as the rate of gut clearance of the solute is first order, the above equation can be depicted as:

Cs =Gs /(Kr +Kg).

Above the saturation levels, as the rate of gut clearance is zero, the equation can be rewritten as:

Cs =(Gs -sorbent capacity)/Kr.

These equations are useful in predicting the efficacy of solute removal from the gut based in vitro studies.

In fact, this model was applied to Friedman's data on urea elimination by the gut in uremic patients using oxystarch oral sorbent (Friedman et al. Trans. Am. Soc. Artif. Intern. Organs 1974 20:161-167). With these data, the model showed that maximum sorbent capacity for native oxystarch oral sorbent was 1.5 g/day which is insufficient to replace dialysis or reduce the frequency of dialysis. This model also predicted that for the same patient data, at a protein catabolic rate of 0.95 grams/kg/24 hours and a urea generation of 5 mg/minute, the maximum sorbent capacity of oxystarch should be 7.2 grams of urea nitrogen/day and the gut clearance rate should be 5.6 ml/minute. Sorbent capacity lower than this, such as 5.4 grams of urea/day will at best delay dialysis by months provided the protein catabolic rate can be held at 0.6 grams/kg/24 hours. Thus, this model is useful in determining optimal results for various formulations of compositions of the present invention to alleviate symptoms of uremia in patients.

The following nonlimiting examples are provided to further illustrate the present invention.

EXAMPLES

Example 1

Source of Sorbents

Oxystarch (dialdehyde starch) was purchased from MPD-Labs, Feasterville, Pa. This is a pharmaceutical grade material (98% pure) with a moisture content of 13% and possessing a minimum 90% oxidized material as per the certificate of analysis by the supplier.

Locust bean gum (minimum 99% pure) was purchased from Sigma-Aldrich, St. Louis, Mo.

Activated charcoal, Supra A, pharmaceutical grade (99.9% purity) was purchased from Norit Corporation of America, Atlanta, Ga.

Each sorbent material was enteric coated with Zein; microencapsulated with ethocel; and microencapsulated with ethocel and then enteric coated with Zein as the shell materials. Encapsulation runs were performed using a disk process. Three separate shell material solutions were prepared: ethocel alone, Zein alone, and Zein in combination with ethocel. After the shell materials were prepared, each sorbent was added to the shell solution (to provide 60% theoretical payload) and mixed to form a dispersion. The dispersion was then sonicated and pumped at approximately 50 grams/minute onto a disk rotating at approximately 20,000 RPM to create microspheres. The microspheres were formed in a heated cone with an inside temperature of approximately 50oC. to evaporate the ethanol and water. The capsules were collected via a cyclone. The native particle size and the particle size after various encapsulations of these sorbents are depicted in Table 1.

                             TABLE 1
                    Encapsulation Formulations
                                            Initial
     Run                                    Particle  Encapsulated
   Num-  Sample                 Shell      Size      Particle Size
     ber  Number  Sorbent       System      (.mu.m)   (.mu.m)
      1   19-011  Dialde-       10% Ethocel Average:  10-100
                  hyde          90% Ethanol 20        Average: 60
                  Starch
      2   19-012  Dialde-       15% Zein    Average:  5-80
                  hyde          76% Ethanol 20        Average: 30
                  Starch         9% Water
      3   19-013  Dialde-      7.7% Zein    Average:  10-100
                  hyde         4.9% Ethocel 20        Average: 50
                  Starch        83% Ethanol
                               4.4% Water
      4   19-014  Locust        10% Ethocel Average:  10-120
                  Bean Gum      90% Ethanol 100       Average: 50
      5   19-015  Locust        15% Zein    Average:  10-200
                  Bean Gum      76% Ethanol 100       Average: 30
                                 9% Water
      6   19-016  Locust      12.3% Zein    Average:  30-200
                  Bean Gum       8% Ethocel 100       Average: 70
                                68% Ethanol
                              11.7% Water
      7   19-017  Activated     10% Ethocel Average:  20-200
                  Charcoal      90% Ethanol 5         Average: 50
      8   19-018  Activated     15% Zein    Average:  20-200
                  Charcoal      76% Ethanol 5         Average: 50
                                 9% Water
      9   19-019  Activated   12.3% Zein    Average:  20-200
                  Charcoal       8% Ethocel 5         Average: 50
                                68% Ethanol
                              11.7% Water
     10   19-020  Alu-          10% Ethocel Average:  10-100
                  minium        90% Ethanol 20        Average: 75
                  Hydroxide
     11   19-021  Alu-          15% Zein    Average:  10-500
                  minium        76% Ethanol 20        Average:
                  Hydroxide      9% Water             300
                                                      needle-like
     12   19-022  Alu-        12.3% Zein    Average:  10-100
                  minium         8% Ethocel 20        Average: 75
                  Hydroxide     68% Ethanol
                              11.7% Water
     13   19-023  Alu-          12% Zein    Average:  10-100
                  minium        79% Ethanol 20        Average: 50
                  Hydroxide      9% Water

scanning electron micrographs (SEMs) of the raw materials including dialdehyde starch, locust bean gum, activated charcoal and aluminium hydroxide and the twelve microencapsulation formulations were also prepared. Run 11, produced rod-like capsules which was caused by the material not being fed directly into the center of the disk or by the solids content being too high. Run 11 was thus repeated as run 13 with the Zein decreased from 15% to 12% and was successful.

In addition to the SEMs of each run, digital photomicrographs were also taken.

Example 2

E. coli DH5 Cells

Genetically engineered E. coli DH5 cells are obtained from Organica Inc. Valley Forge, Pa. The cells are seed cultured, grown, harvested and microencapsulated in accordance with procedures described by Chang and Prakash (Biotechnology and Bioengineering 1995 46:621-26).

Example 3

Formulations

Relative in vitro efficacy of oxystarch, locust bean gum and activated charcoal in native (N), enteric coated (E), microencapsulated (M), and microencapsulated with enteric coating (ME) alone and in various combinations as shown in Table 2 is assessed.

                             TABLE 2
                 Sorbent Efficacy Determinations
                                       Amount of     Amount of
                        Amount of     Locust Bean    Activated
        Formulation     Oxystarch         Gum        Charcoal
          Number           (g)            (g)           (g)
             1              0              0            15
             2              0              5            10
             3              0             10             5
             4              0             15             0
             5              5              0            10
             6              5              5             5
             7              5             10             0
             8             10              0             5
             9             10              5             0
            10             15              0             0

As shown in Table 2, a three level three variable factorial formulation design is used with the constraint that sum total of the ingredients is constant at 15 grams. This design permits evaluation of individual sorbents (formulation numbers 1, 4 and 10), binary combinations (formulation numbers 2, 3, 6, 7, 8 and 9) and a single ternary 1:1:1 combination of sorbents (formulation number 5).

The efficacy of various concentrations of E. coli DH5 cells (5, 10 and 15 grams) in native form and APA (alginic acid-polyglycolide-alginate) microencapsulated form is then assessed.

Efficacy determinations are also made on formulations as depicted in Table 3 containing both sorbents and E. coli DH5.

                             TABLE 3
        Formulation of sorbents plus E. coli DH5 efficacy
                          determinations
                              Locust     Activated   APA E. coli
    Formulation  Oxystarch   Bean Gum    Charcoal     DH5 cells
      Number        (g)         (g)         (g)          (g)
         1           5           5           5            5
         2           5           5           5           10
         3           5           5           5           15
         4           5           5          10            5
         5           5           5          15            5
         6           5          10           5            5
         7           5          15           5            5
         8          10           5           5            5
         9          15           5           5            5


As shown in Table 3, a three level four variable factorial design is used to evaluate the addition of APA-microencapsulated E. coli DH5 cells with constraints that the amount of each ingredient not exceed 15 grams and the maximum amount of the total formulation not exceed 25 grams.

From the experimental observations and determinations of Table 2, only those specific modified forms demonstrating highest sorbent efficacy both independently and in binary combination will be used in these formulations studies with APA microencapsulated E. coli DH5 cells.

A sorbent coating (E, M or ME) will then be selected for ternary sorbent formulation and integration with microencapsulated E. coli DH5 cells.

Example 4

In vitro Efficacy Evaluations

A simulated gastric fluid composed of NaCl, HCl and pepsin in distilled water and adjusted to pH 1.2 is prepared according to U.S. Pharmacopeia procedures for stability testing of formulations under acidic pH and gastric conditions. Every modified sorbent material, and binary and ternary formulation is tested by stirring a quantity of approximately 5 grams into a test solution of simulated gastric juice at 37oC. for 1 to 2 hours to ascertain the integrity of the modified sorbent.

A simulated synthetic intestinal fluid, composed of monobasic potassium hydrogen phosphate, sodium hydroxide, pancreatin mix and distilled water, is also prepared and adjusted to pH 7.5 according to the test solution preparations in U.S. Pharmacopeia. The intestinal fluid is fortified with uremic solutes to make a solution of 150 milligrams of urea, 30 milligrams of creatinine, and 30 milligrams of uric acid per 100 milliliters of synthetic intestinal fluid.

To vary the concentrations, this stock solution is diluted with non-fortified intestinal stock solution to make 75% and 50% concentrations of variable uremic intestinal fluid solutions. Initially 100%, 75% and 50% concentration uremic intestinal fluid solutions are evaluated with a 15 gram sorbent formulation containing S grams each of oxystarch, locust bean gum and activated charcoal. From these data, various experimental parameters including, but not limited to volume, concentration of uremic intestinal fluid, and time of pre- and post-treatment can be optimized. Optimal parameters are then used for all additional sorbent evaluations, formulations and experimental determinations. All experimental observations are made in triplicate.

However, initially, sorbent/formulation test runs of 5, 10 or 15 grams of sorbent or formulation are treated with 500 ml of fortified intestinal fluid of different concentrations in a graduated measuring cylinder and gently shaken for 8 hours. Samples are drawn from the supernatant at one hour intervals, centrifuged if necessary, and analyzed for urea creatinine and uric acid via commercially available kits (Sigma Diagnostics Company, St. Louis, Mo.). Once the adsorption capacity and equilibration times are determined, this period, estimated to be at least 2 hours, will be used.

All formulations shown in the Tables will then be tested. In these tests, 1.5 grams of sorbent formulation is treated with 50 ml of fortified intestinal fluid in a graduated measuring cylinder. The suspension is gently shaken. A sample is withdrawn every hour and analyzed for urea, creatinine and uric acid. The sediment volume is measured for all time intervals and used to determine the water absorbing capacity of each formulation. A plot of the time versus the amount of solute adsorbed per gram of formulation is also obtained for each formulation and the maximum capacity of sorbent formulation and equilibration time for each formulation is calculated. Identical experiments are performed with unencapsulated and encapsulated E. coli DH5 cells to determine urea utilization. Based upon the results of these experiments, five optimized mixtures of modified sorbent formulations with microencapsulated E. coli DH5 cells will be selected for studies in the TNO computer controlled Gastro-Intestinal track model, also referred to as the Dutch stomach model, and for studies in animals.

Example 6

TNO Gastro-Intestinal Model (TIM)

The TNO gastrointestinal model (TIM) simulates very closely the successful dynamic conditions in the lumen of the gastrointestinal track. Dynamic parameters that are simulated include: food and drink intake; the pH curves and the concentrations of enzymes and proenzymes in the stomach including saliva and small intestines including pancreatic juices; the concentration of bile in different parts of the gut; the kinetics passage of chyme through the stomach and small intestines; and the adsorption of water soluble digestive products and water. In the large intestinal model a complex high density microflora of human origin ferments the undigested food compounds in a natural colonic environment simulating pH values, absorption of water, and absorption of microbial metabolites such as short chain fatty acids and gas. Accordingly, this model is used to evaluate the fate of various formulations of compositions of the present invention in both the small and large intestines.

Example 7

In Vivo Studies

Rats weighing approximately 150+15 grams, with a degree of chronic renal failure (CRF) similar to that found in humans with end-stage renal disease approaching the initiation of dialysis are used to test the effects of orally administered microencapsulated sorbents and E. coli DH5 cells at removing uremic toxins that accumulate in CRF and in reducing uremic symptoms. Overall, there are 4 groups including a control group, a group with chronic renal failure and 2 groups with acute renal failure. Specifically, male rats weighing 250-300 grams, approximately 8 weeks in age, are purchased from Charles River or Harlan and housed in cages which prohibit rats from any access to their feces. Baseline measurements of standard clinical chemistries as well as measurements of compounds considered to be uremic toxins are determined for all animals. Rats are then made either acutely uremic or chronically uremic by surgical procedures.

Acute renal failure is produced by bilateral nephrectomy in accordance with procedures described by Waynforth, H. B. and Flecknell, P. A. Nephrectomy. In: Experimental and surgical techniques in the rat. 2nd ed., 1992, Academic Press (Harcourt, Brace, Jovanovich), London, pp. 29, 274-275. After surgery, rats are randomly paired into age or size matched groups and pair fed. Rats are fed by intragastric administration by a curved dosing needle. One group is treated with oral feeding of sorbents along with Kayexylate to control potassium (treated group). The other group receives Kayexylate alone for potassium control only (control group). Both groups are closely monitored for at least 7 to 10 days. If sorbents are effective, some prolongation of life will be observed in the treated groups as compared to the nontreated group.

Chronic renal failure (CRF) is produced by a 2-stage surgical procedure similar to that of the 5/6 nephrectomy model disclosed by Niwa et al. (Miner. Electr. Metab. 1997 23:179-184) and Einbacher and Carter (J. Exp. Med. 1966 123:239-250) but with some modifications found to give a more profound degree of renal failure similar to people closely approaching the need for hemodialysis. In this modified procedure, a soft plastic box is sutured around the remnant kidney to prevent excessive hypertrophy following contralateral nephrectomy. This also aids in controlling organ bleeding.

Specifically, a 2 stage approach is used. On the day of the proposed surgery, food is withheld for one hour. The animal is then anesthetized with the inhalation agent, isoflurane (FORANE). The anesthetized rat is placed on its ventral side, left to right of the surgeon. Both flanks are minimally cleaned of fur with an Oster shaver and prepped with Betadine. A sterile field is prepared on the rat's left flank. A dorsoventral incision is made into the abdomen cavity, down the side of the rat near to the costal border of the thorax on the left side. The left kidney is freed of connective tissue and is pulled out gently, preferably by grasping the perirenal fat. The adrenal gland, which is attached loosely to the anterior pole of the kidney by connective tissue and fat, is gently freed by tearing the attachments. The kidney is positioned to have both poles ligated close to the point where the renal artery enters the organ. A loose lasso of new 4.0 monofilament silk is placed around the upper pole and tied tightly taking care not to break the knot. A double reef knot is used. The organ is examined for excessive bleeding. If necessary, diathermy is used to stop oozing and oxycel is used on the cortex. The same procedure is repeated on the lower pole. The remnant kidney is encased in a pre-made plastic, preferably SARAN wrap, box and secured. The organ is then placed back into the abdomen and the incision closed in 2 layers. The area is swabbed with Betadine and the animal allowed to recover. An analgesic, buprenorphine (0.25 mg/kg) is administered to relive pain. About 3 to 4 weeks later the right kidney is removed. In this surgery, an abdominal approach is used to permit examination of the remnant kidney. The anesthesia is the same, but a midline incision is made along the linea alba, minimizing bleeding. The bowel is gently moved and the left remnant kidney observed to insure some function. Adjustments to the box are made if necessary. Assuming all is well with the left kidney, the right kidney is exposed and freed from its capsule (leaving the adrenal) and then removed by placing a ligature around the renal blood vessels. Another ligature is placed around the ureter as far from the kidney as possible, towards the midline, but without damaging or occluding any collateral blood vessels that may be encountered. The ligature is tied securely with a double reef knot, and the blood vessels are transected next to the kidney, which is then removed. The incision is closed, an analgesic is given and the animal is permitted to recover in a warm area.

Serum creatinine levels of 2.6+0.2 (range 2.3 to 3.5) and blood urea levels of 98+5 with low morbidity (less than 20% by 4 weeks post-op) have been attained consistently in rats with this modified procedure.

Approximately 5 days after the second surgery, contralateral blood is drawn and rats are matched as closely as possible for weight, serum creatinine and blood urea. They are randomly assigned into a series of 4 groups. Groups A and B are pair fed. Group A consists of CRF rats without any test sorbents. Group B rats receive sorbent. A third group, Group C, is given sorbents and allowed free access to food and water. A comparison between Groups B and C shows the effects of uremia on appetite and nutrition. A fourth, sham operated group, Group D is used as controls. Rats are observed over a 4 to 7 month period during which they have biweekly blood and urine collected and assayed for dimethyl- and/or trimethyl-amine via gas chromatography as described by Dunn et al. Analytical Chemistry 1976 48:41-44. Animals are also weighed weekly and blood pressure and urine osmalities are measured monthly. They are assessed daily for appetite by following food and water intake. Timed urine collections are also performed monthly and spot urine collected biweekly. Skinfold thickness is also assessed as an additional nutritional measurement. Rats are sacrificed at 7 months and terminal bloods are drawn for clinical chemistries as well as other specific tests. Blood, urine and brain tissue are also assayed for dimethylamine.

For these studies, sorbents are in a suspension form in sterile saline and are administered orally to the rats using a 12 gauge gastric lavage tube.

Claim 1 of 4 Claims

What is claimed is:

1. A microencapsulated and enteric coated composition comprising:

a) a mixture of sorbents with specific adsorption affinities for uremic toxins wherein the sorbents comprise oxystarch, locust bean gum and activated charcoal; and

b) a bacteria which metabolizes urea and ammonia, wherein the microencapsulation and enteric coating protects a patient taking said composition from microbial infection by said bacteria, and wherein the enteric coating disintegrates and dissolves at or above a pH of 7.5.



____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]